Cytosorbents Co. (NASDAQ:CTSO) Short Interest Update

Cytosorbents Co. (NASDAQ:CTSO) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,370,000 shares, an increase of 5.4% from the November 15th total of 1,300,000 shares. Based on an average daily trading volume, of 123,700 shares, the short-interest ratio is presently 11.1 days.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. CM Management LLC grew its position in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter valued at $51,000. Finally, Sargent Investment Group LLC lifted its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on CTSO shares. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com began coverage on shares of Cytosorbents in a research note on Thursday. They issued a “hold” rating for the company.

Cytosorbents Stock Up 13.4 %

Shares of Cytosorbents stock opened at $1.01 on Monday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The business has a 50-day moving average of $0.98 and a 200-day moving average of $1.02. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The company has a market capitalization of $55.23 million, a PE ratio of -2.81 and a beta of 0.57.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.